Carol Ann Huff, MD discusses how the approval of additional bispecific antibodies for multiple myeloma might change the treatment selection process, highlighting considerations for sequencing of agents and combination therapy.
IASO Bio Announces NMPA s IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.